Share this article on:

CANDIDA ALBICANS AND NON-ALBICANS BLOODSTREAM INFECTIONS IN ADULT AND PEDIATRIC PATIENTS: COMPARISON OF MORTALITY AND COSTS

Moran, Cassandra DO*†; Grussemeyer, Chelsea A. BSPH*; Spalding, James R. PharmD, MS; Benjamin, Daniel K. Jr. MD, MPH, PhD*†; Reed, Shelby D. PhD

The Pediatric Infectious Disease Journal: May 2009 - Volume 28 - Issue 5 - p 433-435
doi: 10.1097/INF.0b013e3181920ffd
Brief Reports

We compared length of stay, inpatient costs, and mortality associated with Candidaalbicans and non-albicans bloodstream infections in adults and children. Compared with adults, children with Candida bloodstream infections had longer lengths of stay (36.7 vs. 20.7 days; P < 0.001) and higher inpatient costs ($133,871 vs. $56,725; P < 0.001) but lower mortality (28.3% vs. 43.5%; P < 0.001).

From the *Duke Clinical Research Institute, Durham, NC; †Department of Pediatrics, Duke University School of Medicine, Durham, NC; ‡Astellas Pharma US, Inc., Deerfield, IL; and §Department of Medicine, Duke University School of Medicine, Durham, NC.

Accepted for publication October 21, 2008.

Supported by a research agreement between Duke University and Astellas Pharma US, Inc., Thrasher Research Fund (to D.K.B.), and by grant HD-044799-04 from the National Institute of Child Health and Human Development (to D.K.B.).

Dr. Spalding is an employee of Astellas Pharma US. Dr. Benjamin received research support in the past year from Astellas, Biosynexus, Cape Cod Associates, Pfizer, and Rockeby; support for fellowship training programs in the past year from AstraZeneca, Johnson & Johnson, The Medicines Company, and MedImmune; research support in the past 5 years from MedImmune, Nabi Biopharmaceuticals, and Vicuron; and grant support for educational programs in the past 5 years from Ross. Dr. Reed has received research support from Actelion, Arthritis Foundation, Astellas Pharma US, Bristol-Myers Squibb, Inspire Pharmaceuticals, Johnson & Johnson, Medtronic, Merck, and Theravance. Dr. Reed has made available online a detailed listing of financial disclosures (http://www.dcri.duke.edu/research/coi.jsp). No other financial disclosures were reported.

Address for correspondence: Shelby D. Reed, PhD, Center for Clinical and Genetic Economics, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715. E-mail: shelby.reed@duke.edu.

© 2009 Lippincott Williams & Wilkins, Inc.